VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis

CX3CR1 has been identified as a highly attractive target for several therapeutic interventions. Despite this potential, no potent antagonists, either small molecule or monoclonal antibody, have been identified. Here we describe the lead finding and engineering approach that lead to the identificatio...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Sarah Low, Haixia Wu, Kavita Jerath, Annette Tibolla, Birgit Fogal, Rebecca Conrad, Deborah Webb, Margit MacDougall, Steven Kerr, Valentina Berger, Rajvee Dave, Jorge Villalona, Lynn Pantages, Jennifer Ahlberg, Hua Li, Diane Van Hoorick, Cedric Ververken, John Broadwater, Alisa Waterman, Sanjaya Singh, Rachel Kroe-Barrett
التنسيق: Artigo
اللغة:Inglês
منشور في: Taylor & Francis Group 2020-01-01
سلاسل:mAbs
الموضوعات:
VHH Antibodies
GPCR
atherosclerosis
BI 655088
biophysical assessment
pharmacokinetic profile
الوصول للمادة أونلاين:https://www.tandfonline.com/doi/10.1080/19420862.2019.1709322
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة